Rapilog^TM

Indication:
Type 1 and Type 2 Diabetes Mellitus, Gestational Diabetes Mellitus.

Dosage & Administration:
Rapilog^TM has a faster onset of action, Rapilog^TMshould generally be given immediately before a meal. When necessary Rapilog^TM may be given soon after a meal. Dosage of Rapilog^TM is individual and determined on the basis of the physician's advice in accordance with the needs of the patient. It should normally be used in combination with long-acting insulin given at least once a day. The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by Rapilog^TM and the remainder by long-acting insulin. Adjustment of dosage may also be necessary if
patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.
Subcutaneous Injection
Rapilog^TM should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because Rapilog^TM has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal
Intravenous Use
Rapilog^TM can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, Rapilog^TM should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. Rapilog^TM has been shown to be stable in infusion fluids such as 0.9% sodium chloride.

Preparation:
Rapilog^TM Injection: Each box contains 3 ml glass vial.
Rapilog^TM Pen Cartridge: Each box contains 3 ml glass Cartridge.